Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
YES
DIRECT
ATG contains antibodies that bind CD28 on T cells, leading to complement-dependent lysis and Fc-mediated ADCC/phagocytosis that depletes CD28+ cells.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
YES
DIRECT
ATG contains antibodies that bind CD11a (LFA-1) on T cells; antibody-coated cells are lysed by complement and cleared via Fc-mediated ADCC/phagocytosis.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
YES
DIRECT
ATG antibodies bind CD18 (LFA-1 beta) on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting those cells.
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
YES
DIRECT
rATG contains antibodies that bind HLA class I (including HLA-C) on cell surfaces, triggering complement-dependent cytotoxicity and Fc-mediated ADCC/phagocytosis, leading to cell death.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
YES
DIRECT
ATG contains antibodies that bind CD45 on leukocytes (including T cells) and induce complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting CD45-expressing cells.